Shanghai Henlius Biotech Drug Pipeline

Shanghai Henlius Biotech maintains a substantial clinical portfolio, with 54 active trials out of 89 total registered since 2008. Clinical activity spans Phase 1 (19 trials), Phase 2 (29 trials), and Phase 3 (13 trials). The company's research is heavily concentrated in oncology, which accounts for all active clinical programs. Within oncology, the portfolio focuses on solid tumors (advanced), non-small cell lung cancer (NSCLC), breast cancer, small cell lung cancer (SCLC), and colorectal cancer. Several programs in these indications are in late-stage development, with Phase 3 trials ongoing in solid tumor (advanced), NSCLC, breast cancer, SCLC, and colorectal cancer. Beyond oncology, Henlius has limited activity in immunology, with no active trials in ophthalmology, respiratory disease, or infectious disease. The strong weighting toward oncology and the presence of multiple Phase 3 trials suggest a focus on near-term catalysts within this therapeutic area.